Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute and an Instructor in Medicine at the Harvard Medical School, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

At doses of 4 mg/kg or higher, the overall response rate, including minimal response, was over 60%, Laubach states. Additionally, the rate of partial response or better was in the range of 40% to 45%, as defined as a 50% reduction in monoclonal protein.

In general, daratumumab was well tolerated. As expected, infusion reactions were observed, specifically early on in the trial. The leading infusion reaction was bronchospasm, Laubach notes. In general, the early administration of supportive medications, such as corticosteroids, seems to help alleviate some of these conditions, making the drug overall well tolerated.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

ASH Annual Meeting and Exposition

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma. 

Dr. Laubach on the Efficacy of Daratumumab in Myeloma